The landscape is the wild west
Andrea Corona Altimmunes GLP-1 drug shows positive results for alcohol use disorder On Tuesday, Altimmune announced topline data from their Phase 2 RECLAIM trial showing that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly reduced the number of heavy drinking days compared to placebo in patients with moderate to severe alcohol use disorder
Radevski, F., Peraic, P., Maek, T., Starevi, K., Krezic, I., Pavlov, K., Drmic, D., Kralj, T., Seiwerth, S., Sikiric, P., & Kokot, A
Expert Swap: Like CJC-1295, Sermorelin also promotes healthy body composition by increasing growth hormone (15)
Once it's liquid, the refrigerator is its only safe home